Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576980 | 0.88 | ALDH1A1 (0.54) | GAATDP1POLBALDH1A1NAAA | |
| SCHEMBL11676519 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11676086 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL10603151 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11677614 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL23471450 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11676939 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11676081 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11679748 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE | |
| SCHEMBL11677626 | 0.84 | NAAA (0.60) | ALDH1A1NAAADGKAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| EP-1380121-B1 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| US-7087784-B2 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN (US) | 2006-08-08 | — | — | US | disclosed |
| US-6887995-B2 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040220407-A1 | Process to prepare oxazolidinones | PERRAULT WILLIAM R | 2004-11-04 | — | — | US | disclosed |
| EP-1380121-A2 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20020169312-A1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002085849-A2 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220407-A1 | Process to prepare oxazolidinones | CYP3A5, OXA1L, CYP3A4 | GAA 997/4885TDP1 3848/4885POLB 380/4885 |
| US-20020169312-A1 | Process to prepare oxazolidinones | CYP3A5, OXA1L, CYP3A4 | GAA 997/4885TDP1 3848/4885POLB 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.